| Gordana Bjekic, MD | |
|
21355 E Dixie Hwy, Ste 102, Aventura, FL 33180-1239 | |
| (305) 932-2552 | |
| Not Available |
| Full Name | Gordana Bjekic |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 34 Years |
| Location | 21355 E Dixie Hwy, Aventura, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699859496 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | ME 71407 (Florida) | Primary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | ME 71407 (Florida) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aventura Hospital And Medical Center | Aventura, FL | Hospital |
| St Mary's Medical Center | West palm beach, FL | Hospital |
| Broward Health North | Pompano beach, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nikhil Bhardwaj Md Pa | 1153451802 | 2 |
| Nuview Telehealth Llc | 8022166974 | 60 |
| Nuview Telehealth Llc | 8022166974 | 60 |
News Archive
The Washington Post: "President Obama mandated Thursday that nearly all hospitals extend visitation rights to the partners of gay men and lesbians and respect patients' choices about who may make critical health-care decisions for them. ... The president directed the Department of Health and Human Services to prohibit discrimination in hospital visitation in a memo that was e-mailed to reporters ... while he was at a fundraiser in Miami."
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
› Verified 3 days ago
| Entity Name | Inpatient Consultants Of Florida, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396795597 PECOS PAC ID: 4789614785 Enrollment ID: O20050819000018 |
News Archive
The Washington Post: "President Obama mandated Thursday that nearly all hospitals extend visitation rights to the partners of gay men and lesbians and respect patients' choices about who may make critical health-care decisions for them. ... The president directed the Department of Health and Human Services to prohibit discrimination in hospital visitation in a memo that was e-mailed to reporters ... while he was at a fundraiser in Miami."
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
› Verified 3 days ago
| Entity Name | Nuview Telehealth Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538300181 PECOS PAC ID: 8022166974 Enrollment ID: O20090501000425 |
News Archive
The Washington Post: "President Obama mandated Thursday that nearly all hospitals extend visitation rights to the partners of gay men and lesbians and respect patients' choices about who may make critical health-care decisions for them. ... The president directed the Department of Health and Human Services to prohibit discrimination in hospital visitation in a memo that was e-mailed to reporters ... while he was at a fundraiser in Miami."
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
› Verified 3 days ago
| Entity Name | Nikhil Bhardwaj Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427279488 PECOS PAC ID: 1153451802 Enrollment ID: O20100608000049 |
News Archive
The Washington Post: "President Obama mandated Thursday that nearly all hospitals extend visitation rights to the partners of gay men and lesbians and respect patients' choices about who may make critical health-care decisions for them. ... The president directed the Department of Health and Human Services to prohibit discrimination in hospital visitation in a memo that was e-mailed to reporters ... while he was at a fundraiser in Miami."
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
› Verified 3 days ago
| Entity Name | Aretaeus Telemedicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548490261 PECOS PAC ID: 6002953635 Enrollment ID: O20201028000919 |
News Archive
The Washington Post: "President Obama mandated Thursday that nearly all hospitals extend visitation rights to the partners of gay men and lesbians and respect patients' choices about who may make critical health-care decisions for them. ... The president directed the Department of Health and Human Services to prohibit discrimination in hospital visitation in a memo that was e-mailed to reporters ... while he was at a fundraiser in Miami."
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gordana Bjekic, MD 21355 E Dixie Hwy, Ste 102, Aventura, FL 33180-1239 Ph: (305) 932-2552 | Gordana Bjekic, MD 21355 E Dixie Hwy, Ste 102, Aventura, FL 33180-1239 Ph: (305) 932-2552 |
News Archive
The Washington Post: "President Obama mandated Thursday that nearly all hospitals extend visitation rights to the partners of gay men and lesbians and respect patients' choices about who may make critical health-care decisions for them. ... The president directed the Department of Health and Human Services to prohibit discrimination in hospital visitation in a memo that was e-mailed to reporters ... while he was at a fundraiser in Miami."
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.
Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it has leased laboratory space (the "NanoShrink Lab") inside the TechPortal, an innovative and brand new technology facilitator center for commercial bioscience research companies which are in most cases based on University of California, Irvine research.
There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.
› Verified 3 days ago
Mr. Solomon Leo Lerer, M.D., F.A.C.G., Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 21110 Biscayne Blvd, # 303, Aventura, FL 33180 Phone: 305-931-6220 Fax: 305-466-4755 | |
Dr. David Yitzchok Manela, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2820 Ne 214th St Ste 902, Aventura, FL 33180 Phone: 213-509-5115 | |
Dr. Steven Kobrin, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2801 Ne 213th St Ste 101, Aventura, FL 33180 Phone: 305-466-7333 Fax: 786-651-2177 | |
Luis Jorge Echarte, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 21110 Biscayne Blvd, Suite 303, Aventura, FL 33180 Phone: 305-466-0030 Fax: 305-466-4755 | |
Nelson Perez Mateu, M.D Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 20601 E Dixie Hwy Ste 340, Aventura, FL 33180 Phone: 786-923-4000 | |
Leonard J Pianko, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 21097 Ne 27th Ct Ste 110, Aventura, FL 33180 Phone: 305-384-4720 Fax: 305-933-1749 | |
Jay E Reinberg, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2845 Aventura Blvd, Suite 247, Aventura, FL 33180 Phone: 305-932-9880 Fax: 305-932-1035 |